Lung Cancer

A pre–new drug application meeting was held with representatives from Turning Point Therapeutics, Inc. and the FDA to discuss repotrectinib as a potential therapeutic option for patients with ROS1-positive advanced non–small cell lung cancer.

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.

Shared insight on the optimal selection and use of single-agent immunotherapy guided by the testing and expression of PD-L1.

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

A brief review of AEs seen with immunotherapy in advanced non–small cell lung cancer followed by advice on how to nuance safety data in this setting.

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Pralsetinib has been approved in Hong Kong, China, for use in treatment-naïve and pretreated adult patients with RET fusion–positive, metastatic non–small cell lung cancer.

Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.

Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.

Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Nir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.